Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Schistosoma mansoni calpain large subunit is a calcium-dependent cysteine protease forming part of a heterodimeric enzyme complex critical for parasite survival. Two homologs, SmCalp1 (also known as Sm-p80) and SmCalp2, are present in the S. mansoni surface (tegument), with SmCalp1 being extensively characterized. This subunit contains characteristic protease domains (PC1, PC2), a membrane association domain (CBSW), and a C-terminal calcium-binding domain (PEF), all required for catalytic activity and substrate binding. Schistosome calpains degrade host proteins, such as fibronectin, contributing to immune evasion, survival, and possibly blood feeding. Targeting the large subunit with inhibitors like E64c impairs parasite viability, underscoring its therapeutic relevance and making it a target of transmission-blocking vaccines and diagnostic efforts.
Inhibition of protease activity, leading to interference with parasite survival or maintenance of host interaction surface
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Schistosoma mansoni calpain large subunit (SmCalp1 (also known as Sm-p80)).